Investigational drug · Phase 2
DX243
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Age-related Hearing Loss.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "DX243"
First trial start
2026
May 13, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DX243", any sponsor or status.
Conditions studied
As listed on its trial records.
- Age-related Hearing Loss
Largest trials
Live from ClinicalTrials.gov: studies naming "DX243" as an intervention, largest first.
DendrogenixIndustry
NCT07637981 · 24 participants (planned) · Start May 13, 2026 · Primary completion Oct 2027
Drug: DX243; Placebo · For: Age-related Hearing Loss
Sites: Liège, Belgium
Newest research
PubMed records naming it or its code names, newest first.
- Beneficial effects of the novel first-in-class compound DX243 on ischemic outcomes following in vitro and in vivo models of stroke.
Marlier Q, Boreux A, Rives A, et al. · Front Stroke 2026
- DX243 counteracts both acoustic trauma-induced reduction in cortical brain oscillations and cochlear synaptopathy.
Fink S, Harasztosi C, Xie L, et al. · Front Pharmacol 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.